These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 6187638)

  • 1. [Preparation of prothrombin complex concentrates with reduced thrombogenicity].
    Dornheim G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(6):856-62. PubMed ID: 6187638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testing for potential thrombogenicity of prothrombin complex concentrates.
    Snape TJ
    Dev Biol Stand; 1979; 44():199-204. PubMed ID: 544295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on prothrombin complex concentrates contact factors, complement components and proteinase inhibitors.
    Steinbuch M; Péjaudier L; Kichenin V; Boffa MC
    Thromb Haemost; 1984 Dec; 52(3):256-62. PubMed ID: 6531751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Production and characterization of a new prothrombin complex concentrate].
    Dornheim G; Wegner H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1985; 112(4):614-28. PubMed ID: 2414191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Thrombogenicity of prothrombin complex concentrates].
    Dornheim G; Klöcking HP; Wulkow R; Storch H; Töpfer G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(4):571-9. PubMed ID: 1714862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Preparation and characterization of an antithrombin III concentrate].
    Dornheim G; Schön R
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(6):870-7. PubMed ID: 6187640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro thrombogenicity tests of factor IX concentrates. II: effects of phospholipids and heparin.
    Prowse CV; Boffa MC; Guthrie C; Pepper DS
    Thromb Haemost; 1980 Feb; 42(5):1368-77. PubMed ID: 7368144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prothrombin fragment 1 + 2, thrombin-antithrombin III-complexes and fibrinopeptide A in spontaneously clotting whole blood in vitro. Effects of heparin addition and antithrombin III deficiency.
    Herren T; Straub PW; Haeberli A
    Thromb Haemost; 1994 Jan; 71(1):49-53. PubMed ID: 8165646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potentially thrombogenic materials in factor IX concentrates.
    Kingdon HS; Lundblad RL; Veltkamp JJ; Aronson DL
    Thromb Diath Haemorrh; 1975 Jun; 33(3):617-31. PubMed ID: 1154317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Modern methods for the manufacture of therapeutic coagulation factors].
    Fuhge P; Gratz P; Geiger H
    Behring Inst Mitt; 1986 Feb; (79):165-76. PubMed ID: 3087341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparin-induced inhibitory effects of a prothrombin complex concentrate on global tests of haemostasis.
    Takeyama M; Sakurai Y; Shima M; Matsumoto T; Nogami K; Tanaka I; Takeda T; Giddings JC; Yoshioka A
    Blood Coagul Fibrinolysis; 2007 Jan; 18(1):1-7. PubMed ID: 17179819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Changes in antithrombin III, prothrombin fragment 1 + 2 and thrombin-antithrombin III complex following implantation of a coronary Palmaz-Schatz stent].
    Dittel M; Haushofer A; Spiel R; Halbmayer WM; Prachar H; Fischer M; Mlczoch J
    Z Kardiol; 1995 Jan; 84(1):22-9. PubMed ID: 7863710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic modulation of thrombin generation associated with human clots by human purified antithrombin alone or in the presence of low molecular weight heparin or unfractionated heparin.
    Meddahi S; Bara L; Fessi H; Samama MM
    Blood Coagul Fibrinolysis; 2000 Jan; 11(1):51-9. PubMed ID: 10691099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on the thrombogenic activities in two prothrombin complex concentrates.
    Hedner U; Nilsson IM; Bergentz SE
    Thromb Haemost; 1979 Oct; 42(3):1022-32. PubMed ID: 315624
    [No Abstract]   [Full Text] [Related]  

  • 15. Anticoagulating and non-enzymatic fibrinolytic activities of heparin-antithrombin III and antithrombin III-heparin-thrombin complexes in vitro and in vivo.
    Kudrjashov BA; Pastorova VE; Lyapina LA
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1983; 110(5):731-42. PubMed ID: 6198257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of different prothrombin complex concentrates--in vitro and in vivo studies.
    Köhler M; Heiden M; Harbauer G; Miyashita C; Mörsdorf S; Braun B; Ernert P; Wenzel E; Rose S; Pindur G
    Thromb Res; 1990 Oct; 60(1):63-70. PubMed ID: 2148989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.
    Ruiz-Sáez A; Hong A; Arguello A; Echenagucia M; Boadas A; Fabbrizzi F; Minichilli F; Bosch NB
    Haemophilia; 2005 Nov; 11(6):583-8. PubMed ID: 16236107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Quality control of prothrombin complex preparations: in vivo and in vitro findings].
    Köhler M; Habauer G; Miyashita C; Braun B; Mörsdorf S; Pindur G; Heiden M; Rose S; Ernert P
    Beitr Infusionsther; 1990; 26():186-9. PubMed ID: 1703826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hepatic coagulopathy--principles and therapeutic statements].
    Thaler E; Kleinberger G
    Leber Magen Darm; 1982 Oct; 12(5):193-7. PubMed ID: 7182699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Heparin and antiheparin in young children. 1. Report: development of a method for determining heparin and antiheparin in the antithrombin-thrombin system].
    Domula M; Weissbach G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(5):808-23. PubMed ID: 6188669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.